Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma

V Castel; A Cañete; C Melero; T Acha; A Navajas; P García-Miguel; T Contra; J Molina; P Galarón; O Cruz

doi:10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u

Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma

Med Pediatr Oncol. 2000 Dec;35(6):724-6. doi: 10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u.

Authors

V Castel¹, A Cañete, C Melero, T Acha, A Navajas, P García-Miguel, T Contra, J Molina, P Galarón, O Cruz

Affiliation

¹ Unidad de Oncología Pediátrica, Hospital Infantil La Fe, Valencia, Spain.

PMID: 11107156
DOI: 10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u

Abstract

Background: Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.

Procedure: Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.

Results: Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.

Conclusions: This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.

Publication types

Clinical Trial

MeSH terms

3-Iodobenzylguanidine / therapeutic use*
Adolescent
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Child
Child, Preschool
Female
Humans
Infant
Male
Neuroblastoma / drug therapy*
Neuroblastoma / mortality
Neuroblastoma / secondary*
Survival Rate

Substances

3-Iodobenzylguanidine